Jia Vision Nord Secures Tens of Millions RMB in Series Angel Funding to Accelerate Domestic Production of High-End Ophthalmic Devices

VCBeat learned第一时间 that recently, Wuxi Brisight Nord Medical Technology Co., Ltd. (hereinafter referred to as "Brisight Nord") has completed an angel round of financing worth tens of millions of RMB. This investment was exclusively provided by Yuanming Xinzhaoyuan.

Brisight Nord founder Dr. Yang Jianxin said: For a long time, mid-to-high-end ophthalmic medical devices in China, especially therapeutic ophthalmic medical devices, have been monopolized by foreign brands. This has, to a certain extent, led to consistently high costs for treating ophthalmic diseases, which in turn has hindered the improvement of treatment rates for these conditions. Brisight Nord has chosen to focus on developing advanced international-level ophthalmic surgical instruments and accompanying consumables as its entry point. Its product line planning includes vitrectomy machines, phacoemulsification machines, intraocular lenses, and excimer lasers. The company is committed to researching and manufacturing high-quality, high-precision, and highly safe ophthalmic medical devices to implement import substitution. Additionally, it will build a comprehensive training and service system to ensure the safe operation of ophthalmic surgeries and the standardized use of its devices. This round of financing will be used for the research and development of the company’s core ophthalmic products and market expansion.

Yuan Ming Xin Zhao Yuan stated：With the rapid development of China's economy and the deepening of the aging process, the demand for diagnosis and treatment of ophthalmic diseases continues to increase. The ophthalmic medical market is a long-term focus of investment both domestically and internationally. Although Wuxi Brisight Nord is an emerging company, its team members all have over 15 years of experience in R&D and operations within the medical device industry. Their developed products are more aligned with the needs of doctors in China and can provide patients with diagnostic and treatment services of international standards at a more economical price, bringing good news to a large number of Chinese patients suffering from ophthalmic diseases.

Yuanming Xinzhaoyuan Fund is an early-stage medical device angel fund under Yuanming Capital, focusing on innovative projects in the early-stage medical device field. The main areas include cardiovascular, neurology, orthopedics, in vitro diagnostics, medical robotics, and advanced radiation therapy industries, with offices in Beijing, Shanghai, Suzhou, and New York.

Team members have extensive business experience and a successful investment track record, focusing on early-stage medical device innovation projects with development potential and growth value. By integrating domestic and international industry resources, they deeply explore the value of target companies and provide value-added services in multiple areas including product R&D validation, registration and clinical trials, and academic promotion. They shape the core advantage of "investment + management" and build a strong industry ecosystem and resource network.